Navigation Links
Specialised Therapeutics Australia Partners with Genomic Health Inc. to Deliver Novel Genomic Test to Breast Cancer Patients
Date:1/7/2014

ology (ASCO)4, St Gallen5 , and the European Society for Medical Oncology (ESMO)6 have all incorporated the Oncotype DX test into their guidelines. In the U.K., the National Institute for Health and Care Excellence (NICE) has recommended Oncotype DX as the only multi-gene breast cancer test for use in clinical practice to guide chemotherapy treatment decisions for patients with early-stage, hormone-receptor-positive, invasive breast cancer.7

"The Oncotype DX technology has played a critical role in predicting benefit of chemotherapy for more than 400,000 oestrogen-receptor-positive breast cancer patients globally in the past 10 years," said Peter Zuendorf, Vice President, International, Genomic Health. "As adoption of Oncotype DX continues to grow, we are delighted to enter this partnership to broaden patient access to this unique test and the important information it provides to enable more individualised breast cancer treatment."

This commercial arrangement between STA and Genomic Health commences from 1st January 2014.

Oncotype DX, Recurrence Score and DCIS Score are trademarks of Genomic Health, Inc.

Contact

Emma Power
Monsoon Communications
0419 149 525
emmap@monsoon.com.au

About Specialised Therapeutics Australia, Pty Ltd

Specialised Therapeutics Australia Pty Ltd (STA) is a biopharmaceutical company dedicated to working with leading pharmaceutical companies worldwide to provide acute care therapies for high unmet medical needs to people living in Australia and New Zealand. The STA therapeutic portfolio and pipeline at present encompasses oncology and infectious diseases. STA also has interests in the therapeutic areas of respiratory, dermatology, endocrinology and central nervous system (CNS). Additional information can be found
'/>"/>

SOURCE Specialised Therapeutics Australia Pty Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
2. Study Updates, Notices, Quarterly Reports, and Revenue Guidance Updates - Research Report on NPS Pharmaceuticals, Oramed, PAREXEL, PhotoMedex, and Cell Therapeutics
3. Shield Therapeutics ST10 Delivers Robust Results Meeting both Primary and Secondary Endpoints in the Pivotal AEGIS Phase 3 Programme for the Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease
4. PTC Therapeutics To Present At The J.P. Morgan Healthcare Conference
5. Mast Therapeutics Announces Positive Data In Model Of Heart Failure
6. Moderna Therapeutics to Present at 32nd Annual J.P. Morgan Healthcare Conference
7. Aratana Therapeutics Acquires Okapi Sciences NV
8. Cell Therapeutics Announces Removal of the Partial Clinical Hold on Tosedostat
9. Mederi Therapeutics Closes Funding of $18.5 Million
10. Aratana Therapeutics Provides 2013 Development Update
11. 2013 Report on the International Pain Management Therapeutics Market - Includes Forecast to 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, ... a vegetable-glycol solution for use in portable vaporizers, ... the active ingredients in cannabis, cannabidiol offers consumers ... vaporizer devices, and other vaporizer technology. ... Cannabis naturally contains 483 different compounds which are ...
(Date:7/11/2014)... , July 11, 2014 Patient ... marketing and, consequently, organizations are turning to an ... As part of this evolving approach ... to educate, communicate and engage patients throughout their ... to patient empowerment. By mapping the patient journey ...
(Date:7/11/2014)... July 11, 2014 The consumer marketing ... across industry sectors to better identify winning tools ... to engage with and understand consumers, as new ... make critical purchasing decisions. According ... LLC, one area where organizations can observe a ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2New Technologies Transforming Consumer Marketing Research Playbook 2
... , SOUTH SAN FRANCISCO, Calif., July 8 Rigel Pharmaceuticals, ... Company plans to host a conference call on Thursday, July ... Members of Rigel,s senior management team and the principal investigator ... 2b TASKi2 clinical trial of R788 in rheumatoid arthritis, the ...
... OAKS, Calif., July 7 Amgen (Nasdaq: ... head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in ... advanced breast cancer met its primary and secondary endpoints ... was demonstrated for both delaying the time to the ...
Cached Medicine Technology:Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 3Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 4Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 5Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 6Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 7Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 8
(Date:7/12/2014)... York (PRWEB) July 12, 2014 ... allegations continue to move forward in the federal ... District of Pennsylvania, Bernstein Liebhard LLP reports. According ... District Judge Lawrence F. Stengel has ordered the ... things, Judge Stengel found that the witness’s testimony ...
(Date:7/12/2014)... Casinos in Australia have ... from international and online casinos. Revenue is estimated to ... years through 2014-15. Greater per capita gambling expenditure has ... Rises in discretionary income levels have also assisted revenue ... items such as casino gambling services. Revenue is estimated ...
(Date:7/12/2014)... -- If you make exercise fun, you,ll eat less after ... adults were led on a 1.4-mile walk and were either ... walk. The participants were given lunch after the walk, and ... 35 percent more chocolate pudding for dessert than those who ... experiment, 46 adults were given mid-afternoon snacks after their walk. ...
(Date:7/12/2014)... (HealthDay News) -- Burn injuries increase in the summer as ... burn experts. Among those most vulnerable to these seasonal fire ... and often get burned by putting their hands on the ... the burn unit at Loyola University Medical Center in Maywood, ... adage of ,When you play with fire, you get burned, ...
(Date:7/12/2014)... PA (PRWEB) July 12, 2014 "The second ... it’s uncomfortable and painful to wear shoes," said an inventor ... special sock that prevents this from happening. , He then ... effective way to prevent the second and big toes from ... endurance while wearing shoes. Ergonomic and easy to use, it's ...
Breaking Medicine News(10 mins):Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Make Exercise Fun, Eat Less Afterwards 2Health News:Burn Injuries More Common in Summer 2
... highly effective in preventing the behavioral and academic problems ... a five-year study led by researchers at Lehigh Universitys ... and funded by the National Institute of Mental Health ... children aged 3 to 5 who have shown significant ...
... Diabetes patients could benefit from new research at the ... the intestine that can taste the sugar content of ... receptor that senses sugar and artificial sweeteners is not ... intestine. The discovery will open new avenues for the ...
... misinformation onlineconsequences could be deadly , The Internet ... to spread false ideas about HIV/AIDS, which could have ... paper in PLoS Medicine. , "It may seem remarkable ... is still denial that the virus is the cause ...
... with organ transplants, resigned to a lifetime of anti-rejection ... respite, say researchers at Lucile Packard Children,s Hospital and ... blood sample, the scientists have identified for the first ... small group of patients who beat the odds and ...
... were more likely to be uninsured or covered by ... report in the August issue of Archives of Otolaryngology-Head ... Laryngeal [voice box] cancer is diagnosed in nearly 10,000 ... is among the most common cancers in the upper ...
... STANFORD, Calif. - As U.S. policy experts continue to ... a new study from the Stanford University School of ... group of patients reduce their overall risk of heart ... a cost-effective way. , Case management makes use of ...
Cached Medicine News:Health News:Non-medicinal treatment touted for pre-schoolers with ADHD 2Health News:Non-medicinal treatment touted for pre-schoolers with ADHD 3Health News:Discovery of 'sugar sensor' in intestine could benefit diabetes 2Health News:HIV denialists spread misinformation online -- consequences could be deadly; and more 2Health News:Study provides hope that some transplant patients could live free of anti-rejection drugs 2Health News:Study provides hope that some transplant patients could live free of anti-rejection drugs 3Health News:Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer 2Health News:Stanford study highlights cost-effective method of lowering heart disease risks 2Health News:Stanford study highlights cost-effective method of lowering heart disease risks 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: